Abstract
The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 794-802 |
| Numero di pagine | 9 |
| Rivista | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Volume | 57 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2013 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- Epstein-Barr virus
- hematopoietic stem cell transplantation
- post-transplant lymphoproliferative disorder
- prognostic model
- risk factors
Fingerprint
Entra nei temi di ricerca di 'Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver